Showing papers by "Omar Serri published in 1990"
TL;DR: CV 205-502 appears to be a safe and valuable compound in the treatment of patients with PRL-secreting macroadenomas and among patients for whom computed tomographic scans were available before and after at least 6 months of therapy, definite tumor shrinkage occurred in 6 of 7 patients.
Abstract: CV 205–502, a new long-acting nonergot dopamine agonist, was given to 15 patients (6 women and 9 men) with PRL-secreting pituitary macroadenomas. The compound was administered in a single daily dose for a period of 6–12 months. The treatment resulted in normalization of plasma PRL levels (≤20 μg/L) in 5 of 6 women at a mean dose of 135 μg (range, 75–300 μg) and in 6 of 9 men at a mean dose of 192 μg (range, 75–300 μg). Among patients for whom computed tomographic scans were available before and after at least 6 months of therapy, definite tumor shrinkage occurred in 6 of 7 patients. Libido was improved in 5 of 6 women and in 6 of 8 men, galactorrhea disappeared in all cases (3 women and 1 man) and menses resumed in 3 of 5 women. Plasma testosterone rose to normal levels in 3 of 6 men who were not receiving testosterone injections. The PRL response to TRH was blunted in 4 of 6 patients with normalized basal PRL. Serum total cholesterol was reduced by CV 205–502 treatment in women from 5.35 ± 0.49 to 4.63 ±...
23 citations